Drug Approval Process in Europe - An Outlook
Drug Approval Process in Europe - An Outlook Updated Research Available
RELEASE DATE
22-Dec-2008
22-Dec-2008
REGION
Europe
Europe
Research Code: M2DB-01-00-00-00
SKU: HC01742-EU-MR_06503
$4,950.00
In stock
SKU
HC01742-EU-MR_06503
Description
This research deals with the drug approval process in Europe by focussing on the various marketing authorisation procedures, price controls and parallel trading. A snapshot of the biosimilars approval process is also provided along with the key strategic recommendations.
Table of Contents
Executive Summary of the Drug Approval Process in Europe
- Overview of the European Drug Approval Process
Research Methodology for Drug Approval Process in Europe
- The Methodology
- Scope and Objectives
Major Industry Challenges
- Introduction
- Regulatory Challenges in the European Union
Marketing Authorisation Procedures
- Marketing Authorisation Procedures in Europe
- Comparing the Regulatory Systems in Europe and the United States
Overview of the Price Control and Parallel Trading in Europe
- Analysis of Price Control and Parallel Trading
Approval Process for Biosimilars
- Biosimilars in Europe
Key Findings
- Recommendations for the European Drug Approval Process
Decision Support Database
- Number of Biotech Companies
- Number of Biotetchnology Patents-European Patents Office
- Number of Biotechnology Patents - USA Patents and Trade Mark Office
- Government R&D Investment in Biotechnology
- Private Investment in Biotechnology
Popular Topics
This research deals with the drug approval process in Europe by focussing on the various marketing authorisation procedures, price controls and parallel trading. A snapshot of the biosimilars approval process is also provided along with the key strategic recommendations.
No Index | No |
---|---|
Podcast | No |
Industries | Healthcare |
WIP Number | M2DB-01-00-00-00 |
Is Prebook | No |